valsartan has been researched along with atenolol in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (16.67) | 18.2507 |
| 2000's | 17 (47.22) | 29.6817 |
| 2010's | 12 (33.33) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Faller, B; Wohnsland, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Czendlik, CH; Howald, H; Preiswerk, G; Sioufi, A | 1 |
| Botteri, F; Cifkova, R; Hradec, J; Oddou-Stock, P; Peleska, J; Pintérová, E; Rosolová, H; Thirlwell, J; Zeman, K | 1 |
| Harder, S; Kenedi, P; Rietbrock, N; Schmidt, A; Thürmann, PA | 1 |
| Thürmann, PA | 2 |
| Gottdiener, JS | 1 |
| Devereux, RB | 1 |
| Rapi, J | 1 |
| Derosa, G; Fogari, R; Marasi, G; Mugellini, A; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Corradi, L; Fogari, R; Mugellini, A; Pasotti, C; Preti, P; Rinaldi, A; Zoppi, A | 1 |
| Boschmann, M; Engeli, S; Jordan, J; Kreuzberg, U; Luft, FC; Sharma, AM; Weidinger, G | 1 |
| Adams, F; Boschmann, M; Engeli, S; Franke, G; Jordan, J; Klaua, S; Kreuzberg, U; Luft, FC; Scholze, J; Sharma, AM; Weidinger, G | 1 |
| De Ciuceis, C; Endemann, DH; Ko, EA; Pu, Q; Savoia, C; Schiffrin, EL; Touyz, RM | 1 |
| Savoia, C; Schiffrin, EL; Touyz, RM; Volpe, M | 1 |
| Fletcher, EL; Phipps, JA; Wilkinson-Berka, JL | 1 |
| Jaworski, K; Ninkovic, S; Tan, G; Wilkinson-Berka, JL | 1 |
| Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Zoppi, A | 1 |
| Mourad, JJ; Waeber, B | 1 |
| Achouba, A; Boutouyrie, P; Laurent, S; Trunet, P | 1 |
| Achouba, A; Beaussier, H; Boutouyrie, P; Laurent, S | 1 |
| Cole, JB; Laes, JR; Williams, DM | 1 |
| Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Park, RW; Yoon, D | 1 |
| Abdel-Megied, A; Ahmed, H; Ezike, OF; Kovalenko, S; Logoyda, L; Peleshok, K; Piponski, M | 1 |
3 review(s) available for valsartan and atenolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Therapeutic options in minimizing left ventricular hypertrophy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Humans; Hypertension; Hypertrophy, Left Ventricular; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
[Irbesartan: a new possibility in the treatment of hypertension].
Topics: Acrylates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Benzimidazoles; Benzoates; Biological Availability; Biphenyl Compounds; Controlled Clinical Trials as Topic; Drug Administration Schedule; Enalapril; Half-Life; Humans; Hypertension; Imidazoles; Irbesartan; Losartan; Telmisartan; Tetrazoles; Thiophenes; Valine; Valsartan | 2002 |
16 trial(s) available for valsartan and atenolol
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
Topics: Adrenergic beta-Antagonists; Adult; Angiotensin II; Antihypertensive Agents; Area Under Curve; Atenolol; Blood Pressure; Cross-Over Studies; Drug Interactions; Exercise; Half-Life; Heart Rate; Humans; Male; Metabolic Clearance Rate; Renin; Tetrazoles; Valine; Valsartan | 1997 |
Valsartan and atenolol in patients with severe essential hypertension.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1998 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Echocardiography; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1998 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Angiotensin II; Antihypertensive Agents; Atenolol; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 1999 |
Angiotensin II antagonism and the heart: valsartan in left ventricular hypertrophy.
Topics: Aged; Antihypertensive Agents; Atenolol; Calcium Channel Blockers; Double-Blind Method; Female; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diuretics; Drug Interactions; Heart Ventricles; Humans; Hydrochlorothiazide; Hypertension; Hypertrophy, Left Ventricular; Organ Size; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Research Design; Tetrazoles; Valine; Valsartan | 1999 |
Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men.
Topics: Adult; Analysis of Variance; Antihypertensive Agents; Atenolol; Coitus; Double-Blind Method; Humans; Hypertension; Male; Middle Aged; Testosterone; Tetrazoles; Valine; Valsartan | 2002 |
Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Hormone Replacement Therapy; Humans; Hypertension; Libido; Middle Aged; Postmenopause; Sexual Behavior; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2004 |
Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Blood Glucose; Blood Pressure; Double-Blind Method; Female; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Obesity; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2005 |
The effect of oral glucose loads on tissue metabolism during angiotensin II receptor and beta-receptor blockade in obese hypertensive subjects.
Topics: Adipose Tissue; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Ethanol; Fatty Acids, Nonesterified; Female; Glucose; Glucose Tolerance Test; Glycerol; Humans; Hypertension; Insulin; Kinetics; Lactic Acid; Lipids; Male; Metabolism; Middle Aged; Muscle, Skeletal; Obesity; Tetrazoles; Valine; Valsartan | 2006 |
Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteries; Atenolol; Biopsy; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diastole; Female; Humans; Hypertension; Male; Middle Aged; Organ Culture Techniques; Subcutaneous Tissue; Systole; Tetrazoles; Time; Treatment Outcome; Valine; Valsartan | 2006 |
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Vasodilation | 2007 |
Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Topics: Aged; Amlodipine; Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Atrial Fibrillation; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Electrocardiography; Female; Humans; Hypertension; Male; Middle Aged; Propafenone; Prospective Studies; Secondary Prevention; Tetrazoles; Valine; Valsartan | 2008 |
Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Amlodipine; Antihypertensive Agents; Atenolol; Blood Pressure; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Multivariate Analysis; Probability; Prospective Studies; Severity of Illness Index; Single-Blind Method; Systole; Tetrazoles; Treatment Outcome; Valine; Valsartan; Young Adult | 2010 |
Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure.
Topics: Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Pulse Wave Analysis; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2014 |
Central and cerebral haemodynamic changes after antihypertensive therapy in ischaemic stroke patients: A double-blind randomised trial.
Topics: Aged; Antihypertensive Agents; Atenolol; Biphenyl Compounds; Cerebrovascular Circulation; Double-Blind Method; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Prospective Studies; Pyrimidines; Stroke; Tetrazoles; Treatment Outcome; Valsartan | 2018 |
17 other study(ies) available for valsartan and atenolol
| Article | Year |
|---|---|
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
Topics: Alkanes; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Membranes, Artificial; Octanols; Permeability; Pharmaceutical Preparations; Solubility; Water | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Dilemma of antihypertensive therapy: high blood pressure diminishes, potency sometimes, too].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; Diuretics; Erectile Dysfunction; Humans; Hypertension; Male; Myocardial Infarction; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Retinal dysfunction in diabetic ren-2 rats is ameliorated by treatment with valsartan but not atenolol.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Antihypertensive Agents; Atenolol; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Electroretinography; Female; Hypertension; Neuroglia; Photic Stimulation; Rats; Retina; Tetrazoles; Valine; Valsartan | 2007 |
Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Genetically Modified; Atenolol; Blood Pressure; Body Weight; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Endothelial Cells; Female; Glycated Hemoglobin; Rats; Rats, Sprague-Dawley; Renin; Retinal Vessels; Tetrazoles; Valine; Valsartan | 2007 |
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension.
Topics: Amlodipine; Antihypertensive Agents; Atenolol; Double-Blind Method; Drug Therapy, Combination; France; Humans; Hydrochlorothiazide; Hypertension; Indapamide; Losartan; Perindopril; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Improvement in Hemodynamics After Methylene Blue Administration in Drug-Induced Vasodilatory Shock: A Case Report.
Topics: Amlodipine; Atenolol; Hemodynamics; Humans; Male; Methylene Blue; Middle Aged; Shock; Valsartan; Vasodilation | 2015 |
New liquid chromatography assays for simultaneous quantification of antihypertensives atenolol and valsartan in their dosage forms.
Topics: Antihypertensive Agents; Atenolol; Chromatography, High Pressure Liquid; Valsartan | 2021 |